Skip to main content

Sequenom Sells $7M in MassARRAYs to Samsung in Diagnostics-Discovery Deal

NEW YORK, June 18 - Sequenom today said it sold "multiple" units of its MassARRAY gene-analysis tools to Korean conglomerate Samsung to help it discover diagnostics.
Terms of the agreement call for Sequenom to receive 50 percent of the rights to any drugs developed from genes discovered by the Samsung Advanced Institute of Technology. The genomic tool shop will also receiv a 5-percent royalty on any diagnostic tests Samsung develops using the technology.

Though no other financial details were released, Reuters reported this morning that Samsung bought $7 million worth of the MassARRAY tools. This figure could not be independently verified.


Click here for more information.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.